BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 10, 2025
See today's BioWorld Asia
Home
» EU pharma lobby in China says IP, market access top concerns
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
EU pharma lobby in China says IP, market access top concerns
Oct. 8, 2014
By
Shannon Ellis
No Comments
SHANGHAI – European drug companies may find it hard to bend the ear of the Chinese government on their own. The country is large with numerous stakeholders to take into account as China undertakes its massive health care reform project.
BioWorld Asia